Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors
Laura Fionda, Elena Rossini, Antonio Lauletta, Luca Leonardi, Laura Tufano, Rocco Costanzo, Paolo Marchetti, Marco Salvetti, Matteo Garibaldi, Stefania Morino, Giovanni Antonini
Topics & Concepts
PembrolizumabMedicineDiscontinuationEculizumabExacerbationInternal medicineRefractory (planetary science)CancerComplement systemImmunologyImmunotherapyImmune systemPhysicsAstrobiologyCancer Immunotherapy and BiomarkersComplement system in diseasesColorectal Cancer Treatments and Studies